A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls - Concepedia

Concepedia

Publication | Closed Access

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls

105

Citations

47

References

2015

Year

Timo Vesikari, Nicholas Brodszki, Pierre Van Damme, Javier Díez‐Domingo, Giancarlo Icardi, Lone Kjeld Petersen, Clément Tran, Stéphane Thomas, Alain Luxembourg, Martine Baudin

The Pediatric Infectious Disease Journal

Abstract

In addition to immune responses to HPV 31/33/45/52/58, a 3-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in girls aged 9-15 years. The safety profile was also similar for the 2 vaccines.

References

	Year	Citations

Page 1